Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Enfortumab vedotin, sold under the brand name Padcev, is an antibody-drug conjugate used for the treatment of urothelial cancer. It is a nectin-4-directed antibody and microtubule inhibitor conjugate. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker.
Read the full article on WikipediaLocally advanced (Stage III) or metastatic (Stage IV) urothelial cancer Clinical criteria: The condition must have progressed on/following both: (i) platinum-based chemotherapy, (ii) programmed cell death 1/ligand 1 (PD-1/PD-L1) inhibitor therapy; OR The condition must have progressed on/following platinum-based chemotherapy, whilst PD-1/PD-L1 inhibitor therapy resulted in an intolerance that required treatment cessation, AND Patient must have/have had a WHO performance status score of no greater than 1 at treatment initiation with this drug. AND The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication. Treatment criteria: Patient must be undergoing treatment with this drug for the first time; OR Patient must be undergoing continuing treatment with this drug, with each of the following being true: (i) all other PBS eligibility criteria in this restriction are met, (ii) disease progression is absent.
Working under the parallel aged-care framework? Aged-care equivalent →